恒古骨伤愈合剂定向透药联合塞来昔布胶囊口服治疗膝骨关节炎的临床研究  

Clinical Study on Knee Osteoarthritis by Osteoking Directed Permeation Combined with Celecoxib Capsule

作　　者：刘钦岱 匡浩铭 白林寒 何瀚威 戎宽[2] 匡建军[3] LIU Qindai;KUANG Haoming;BAI Linhan;HE Hanwei;RONG Kuan;KUANG Jianjun(Hunan University of Chinese Medicine,Changsha Hunan 410208,China;Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine,Changsha Hunan 410000,China;Hunan Academy of Traditional Chinese Medicine,Changsha Hunan 410000,China)

机构地区：[1]湖南中医药大学,湖南长沙410208 [2]湖南省中医药研究院附属医院,湖南长沙410006 [3]湖南省中医药研究院,湖南长沙410006

出　　处：《中医药导报》2023年第4期84-87,共4页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：湖南省自然科学基金项目(2022JJ60076);长沙市科技局重点项目(kh2201063);湖南省中医药研究院院级课题项目(202129)。

摘　　要：目的:探讨恒古骨伤愈合剂定向透药联合塞来昔布胶囊治疗膝骨关节炎(KOA)的疗效。方法:将60例KOA肝肾亏虚证患者随机分成对照组和治疗组各30例,对照组患者予塞来昔布胶囊口服治疗,治疗组患者在口服塞来昔布胶囊的基础上联合使用恒古骨伤愈合剂定向透药,12 d为1个疗程,记录治疗前及治疗2个疗程后患者的疼痛视觉模拟评分(VAS评分)、西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分、中医证候评分,检测膝关节液中IL-1β、TNF-α、MMP-3含量。结果:60例患者均完成治疗。治疗组总有效率优于对照组,差异有统计学意义(P<0.05)。两组患者治疗后VAS评分、WOMAC评分、中医证候评分均低于治疗前(P<0.05),且治疗组患者治疗后VAS评分、WOMAC评分、中医证候评分均低于对照组(P<0.05)。两组患者治疗后膝关节液中IL-1β、TNF-α、MMP-3含量均低于治疗前(P<0.05),且治疗组患者治疗后膝关节液中IL-1β、TNF-α、MMP-3含量均低于对照组(P<0.05)。两组患者均未见严重不良反应,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:恒古骨伤愈合剂定向透药联合塞来昔布胶囊治疗KOA肝肾亏虚证疗效显著,能够有效减轻患者疼痛,改善患者膝关节功能,降低膝关节液中炎症因子水平。Objective:To investigate the effect of Osteoking directed permeation combined with celecoxib capsule on knee osteoarthritis(KOA).Methods:A total of 60 patients with KOA of liver-kidney deficiency syndrome were randomly divided into control and treatment groups,with 30 cases in each group.Patients were treated with oral celecoxib capsule in control group,and oral celecoxib capsule combined with targeted permeability of Osteoking in treatment group,12 days as a course.The VAS score,WOMAC score and TCM syndrome score were recorded before treatment and after 2 courses of treatment.The contents of IL-1β,TNF-αand MMP-3 in knee fluid were detected.Results:All 60 patients completed the treatment.The treatment group showed better total effective rate than control group,and the difference was statistically significant(P<0.05).After treatment,the VAS score,WOMAC score and TCM syndrome score of the two groups were lower than before treatment(P<0.05),and the treatment group showed lower VAS score,WOMAC score and TCM syndrome score than control group after treatment(P<0.05).After treatment,the contents of IL-1β,TNF-αand MMP-3 in knee fluid of the two groups were lower than before treatment(P<0.05),and the treatment group showed lower contents of IL-1β,TNF-αand MMP-3 in knee fluid than control group after treatment(P<0.05).No serious adverse reactions were observed in the two groups,and there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The directed permeation of Osteoking combined with celecoxib capsule shows a significant effect on the treatment of KOA of liver-kidney deficiency syndrome,which can effectively reduce the pain of patients,improve the knee joint function and reduce the content of inflammatory factors in knee joint fluid.

关 键 词：膝骨关节炎 肝肾亏虚证 恒古骨伤愈合剂 塞来昔布胶囊 联合用药 IL-1β TNF-α MMP-3 

分 类 号：R274.32[医药卫生—中医骨伤科学]